Abstract
The application of personalized medicine to psychiatry is challenging. Psychoradiology could provide biomarkers based on objective tests in support of the diagnostic classifications and treatment planning. We review potential psychoradiological biomarkers for psychopharmaceutical effects. Although none of the biomarkers reviewed are yet of sufficient clinical utility to inform the selection of a specific pharmacologic compound for an individual patient, there is strong consensus that advanced multimodal approaches will contribute to discovery of novel treatment predictors in psychiatric disorders. Progress has been sufficient to warrant enthusiasm, in which application of neuroimaging-based biomarkers would represent a paradigm shift and modernization of psychiatric practice.
| Original language | English |
|---|---|
| Pages (from-to) | 53-63 |
| Number of pages | 11 |
| Journal | Neuroimaging Clinics of North America |
| Volume | 30 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2020 |
Keywords
- Antidepressants
- Predictive imaging biomarkers
- Psychoradiology
- Stimulants
- Treatment response